Streetbeat News

ASND

Ascendis Pharma A/S

Industry

Biotechnology

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Open

137.28

Mkt cap

8.3B

Volume

157K

High

140.46

P/E Ratio

-17.84

52-wk high

161.00

Low

135.61

Div yield

N/A

52-wk low

111.09

Ascendis Pharma A/S has announced the commercial availability of YORVIPATH® (palopegteriparatide) in the United States for treating hypoparathyroidism in adults. This is the first FDA-approved medicine for this condition, marking a significant milestone for the company.

Portfolio Pulse from

December 19, 2024 | 1:45 pm

The InsiGHTS trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome achieved its primary objective at Week 26, demonstrating a safety and tolerability profile comparable to daily somatropin across all starting dose cohorts.

Portfolio Pulse from

December 16, 2024 | 1:45 pm

Ascendis Pharma's supplemental Biologics License Application for TransCon hGH, aimed at treating adult growth hormone deficiency, has been accepted by the FDA. The PDUFA goal date is set for July 27, 2025.

Portfolio Pulse from

December 12, 2024 | 9:15 pm

Er-Kim has extended its exclusive distribution agreement with Ascendis Pharma A/S to expand the commercialization of its endocrinology portfolio to Eurasian markets. This agreement involves the distribution of three rare endocrinology disease treatments.

Portfolio Pulse from

December 10, 2024 | 12:15 pm

Ascendis Pharma A/S (ASND) held its Q3 2024 earnings call, discussing financial performance and operations with key executives and analysts from major financial institutions.

Portfolio Pulse from

November 15, 2024 | 4:00 am

Ascendis Pharma has reported its third quarter 2024 financial results, highlighting the upcoming U.S. launch of YORVIPATH with availability expected by mid-January 2025. The company also reported ex-U.S. YORVIPATH revenue of €8.5 million for Q3.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

BioMarin Pharmaceutical Inc. reported strong Q3 results with EPS and sales beating expectations. However, William Blair downgraded the stock, citing skepticism about future growth from its clinical pipeline. Despite strong sales from Voxzogo, competition from Ascendis Pharma's new product poses a threat. Analysts have mixed reactions, with some lowering price targets.

Portfolio Pulse from Vandana Singh

October 30, 2024 | 6:42 pm

JP Morgan analyst Jessica Fye maintains an Overweight rating on Ascendis Pharma (NASDAQ:ASND) but lowers the price target from $180 to $174.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 11:50 am

TD Cowen analyst Yaron Werber maintains a Buy rating on Ascendis Pharma (NASDAQ:ASND) and raises the price target from $157 to $160.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 5:15 pm

Ascendis Pharma (NASDAQ:ASND) has significantly outperformed the market over the past decade, with an average annual return of 51.37%. A $100 investment in ASND 10 years ago would now be worth $6,501.23, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 8:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.